Share Name Share Symbol Market Type Share ISIN Share Description
Cello Health Plc LSE:CLL London Ordinary Share GB00B0310763 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +7.00p +5.88% 126.00p 125.00p 127.00p 127.50p 119.00p 119.00p 99,194 12:23:48
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 165.6 8.4 6.3 20.1 132

Cello Health PLC Issue of Equity

20/05/2019 4:29pm

UK Regulatory (RNS & others)


Cello Health (LSE:CLL)
Historical Stock Chart

2 Months : From May 2019 to Jul 2019

Click Here for more Cello Health Charts.

TIDMCLL

RNS Number : 6052Z

Cello Health PLC

20 May 2019

20 May 2019

Cello Health plc

("Cello" or the "Company")

Issue of Equity

Further to the announcement released on 1 February 2017 regarding the acquisition of the assets of Defined Healthcare Research, Inc, and Cancer Progress, LLC ("Defined Health") by the Company, Cello today announces that the first deferred consideration payments to the vendors of Defined Health have now been settled.

To part satisfy the deferred consideration, the Company has applied for the admission of 320,243 new ordinary shares of 10 pence each in the Company ("Ordinary Shares") to trading on AIM, which is expected to occur on 24 May 2019.

Following admission, Cello's issued share capital will consist of 105,545,545 Ordinary Shares, of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company will therefore be 105,092,545 Ordinary Shares.

The above figure (105,092,545 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
 Cello Health plc                        020 7812 8460 
 Mark Scott, Chief Executive 
 Mark Bentley, Group Finance Director 
 Cenkos Securities plc                   020 7397 8900 
 Mark Connelly 
  Harry Hargreaves 
 
 Buchanan 
  Mark Court                             020 7466 5000 
 Jamie Hooper 
 Sophie Wills 
 
 

About Cello Health plc

We are a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. We currently service 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

We enable clients to differentiate their propositions and drive brand success in ever more complex global markets. We deliver our services through nearly 1,000 highly skilled professionals utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, Germany and Asia, with hub offices in New York, Philadelphia, London, Berlin, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOEURUVRKNAVUAR

(END) Dow Jones Newswires

May 20, 2019 11:29 ET (15:29 GMT)

1 Year Cello Health Chart

1 Year Cello Health Chart

1 Month Cello Health Chart

1 Month Cello Health Chart
Your Recent History
LSE
CLL
Cello Heal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190718 17:57:24